Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2002 1
2003 1
2004 1
2005 1
2006 1
2007 1
2013 2
2014 1
2015 3
2016 3
2017 2
2019 4
2020 5
2021 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking.
Lepack AE, Werner CT, Stewart AF, Fulton SL, Zhong P, Farrelly LA, Smith ACW, Ramakrishnan A, Lyu Y, Bastle RM, Martin JA, Mitra S, O'Connor RM, Wang ZJ, Molina H, Turecki G, Shen L, Yan Z, Calipari ES, Dietz DM, Kenny PJ, Maze I. Lepack AE, et al. Among authors: farrelly la. Science. 2020 Apr 10;368(6487):197-201. doi: 10.1126/science.aaw8806. Science. 2020. PMID: 32273471 Free PMC article.
Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3.
Farrelly LA, Thompson RE, Zhao S, Lepack AE, Lyu Y, Bhanu NV, Zhang B, Loh YE, Ramakrishnan A, Vadodaria KC, Heard KJ, Erikson G, Nakadai T, Bastle RM, Lukasak BJ, Zebroski H 3rd, Alenina N, Bader M, Berton O, Roeder RG, Molina H, Gage FH, Shen L, Garcia BA, Li H, Muir TW, Maze I. Farrelly LA, et al. Nature. 2019 Mar;567(7749):535-539. doi: 10.1038/s41586-019-1024-7. Epub 2019 Mar 13. Nature. 2019. PMID: 30867594 Free PMC article.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Oza AM, et al. Among authors: farrelly l. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115797 Free PMC article. Clinical Trial.
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M; Gynecologic Cancer InterGroup (GCIG) symptom benefit committee. Kurtz JE, et al. Among authors: farrelly l. Gynecol Oncol. 2021 May;161(2):502-507. doi: 10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19. Gynecol Oncol. 2021. PMID: 33612336 Review.
Histone H3Q5 serotonylation stabilizes H3K4 methylation and potentiates its readout.
Zhao S, Chuh KN, Zhang B, Dul BE, Thompson RE, Farrelly LA, Liu X, Xu N, Xue Y, Roeder RG, Maze I, Muir TW, Li H. Zhao S, et al. Among authors: farrelly la. Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2016742118. doi: 10.1073/pnas.2016742118. Proc Natl Acad Sci U S A. 2021. PMID: 33526675 Free PMC article.
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S. Elyashiv O, et al. Among authors: farrelly l. Int J Gynecol Cancer. 2021 Jan;31(1):134-138. doi: 10.1136/ijgc-2020-002073. Epub 2020 Oct 23. Int J Gynecol Cancer. 2021. PMID: 33097567
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y, Hackshaw A, Wheeler GM. Fennell DA, et al. Among authors: farrelly l. Clin Cancer Res. 2020 Sep 15;26(18):4748-4755. doi: 10.1158/1078-0432.CCR-20-1306. Epub 2020 Jul 15. Clin Cancer Res. 2020. PMID: 32669375 Free article. Clinical Trial.
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development.
Concin N, Ray-Coquard I, Glasspool RM, Braicu E, Farrelly L, Votan B, Mirza MR, Gonzalez Martin A, Vergote I, Pignata S. Concin N, et al. Among authors: farrelly l. Int J Gynecol Cancer. 2020 Jun;30(6):730-734. doi: 10.1136/ijgc-2020-001464. Epub 2020 May 12. Int J Gynecol Cancer. 2020. PMID: 32404377 No abstract available.
30 results